Cenerx logo
home | search
scientists
program banner

CENERX NEWS & EVENTS

9-DEC-11
CeNeRx BioPharma Completes $4.85 Million Financing
Funds to Support Completion of Phase II Trial of TriRimaTM in Treatment Resistant Depression
Reports Good Progress in TriRima Phase II Trial and FDA Approval of IND to Assess CXB909 as Potential Treatment for Alzheimer's Disease
Read more...
8-FEB-11
CeNeRx Announces FDA IND Approval for Its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results from First Human Study
Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity and Good Safety in Early Studies
CEO Barry Brand to Serve as Panelist on BIO CEO Therapeutic Workshop Panel
Read more...
1-JAN-11
CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Follows Successful Safety Studies of New and Improved Formulation of this Novel Antidepressant
Learn More about CeNeRx and TriRima at Biotech Showcase™ 2011
Read more...
02-NOV-10

CeNeRx's Novel Antidepressant Tririma™ Demonstrates Key Safety Benefit In Pivotal Safety Study
New Modified Release Formulation of Novel MAO Inhibitor Achieves Sustained High Levels of Drug Exposure While Showing No Signs of Cardiovascular Effects;
TriRima's Potential as First Monotherapy for Treatment Resistant Depression to be Tested in Phase II Trial Scheduled to Begin Later this Month;
Learn More about TriRima at Windhover's Therapeutic Area Partnerships Meeting as a 2011 "Top 10 Neuroscience Project to Watch"
Read more...
13-AUG-10
CeNeRx BioPharma Completes $13 Million Series C Financing
New Funds to Support Expanded Phase II Trial of Novel Antidepressant TriRima™
Read more...
12-JAN-10

New Clinical Study Shows Anxiolytic Potential of CeNeRx’s Novel Mechanism HPA Axis Modulator Compounds.
Hypothalamic-Pituitary-Adrenal (HPA) Axis Modulator CXB722 Demonstrates Promising Activity in Trier Social Stress Test;
Positive Study Results Confirm Distinctive Mechanism of Action and Set the Stage for Further Clinical Development of CXB722 Prodrug Ayrene
Read more...
07-DEC-09

Publication in Neuropsychopharmacology Confirms CeNeRx’s Novel RIMA Antidepressant TriRima™ Selectively and Reversibly Inhibits MAO-A.
Innovative PET Imaging Studies Confirm TriRima™ Demonstrates Reversible Inhibition of MAO-A in the Human Brain;
Represents First Validation in Humans of Mechanism of RIMA Antidepressants

Read more...
16-JUN-09

CeNeRx Biopharma Completes $9 Million Financing.
New Funds to Support Advancement of Multiple Novel Programs for CNS Disorders

Read more...
16-JUN-09

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders.
Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically
Broad Potential Applications Include Neuropathies, Alzheimer’s and Huntingdon’s Disease and Others
Read more..
1-APR-09

CeNeRx BioPharma Awarded New Patent for Its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors.
By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds
.
Read more...
12-FEB-09

CeNeRx Biopharma Reports Robust Patient Enrollment in Phase II Trial of Its Novel Antidepressant Agent TriRima™.
Rapid Enrollment of Targeted Patients Seen as an Indicator of High Unmet Need for Improved Therapeutic Options in this Patient Group.
Read more..
17-OCT-08

CeNeRx BioPharma Completes $15 Million Series B Financincing.
New Funds Will Support Phase II Trial of Novel Antidepressant Tyrima™ and Advancement of Cannabinoid Compounds.

Read more...
17-OCT-08

CeNeRx BioPharma  Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima™.
Read more...
22-JUL-08
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima™.
State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties. Results Support Initiation of Phase II Clinical Trials
Read more...
12-MAY-08

CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development.
Former GSK Clinical Development Head Brings Over 20 Years of Clinical and Product Development Expertise to the Company’s CNS Portfolio
Read more...
16-JAN-08
CeNeRx BioPharma Announces Successful Completion of Phase I Clinical Program for Novel Antidepressant Agent Tyrima™
Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies
Read more...

News Archive >